Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Share-based Compensation (2016 - 2025)

Rein Therapeutics filings provide 10 years of Share-based Compensation readings, the most recent being $257000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation rose 93.23% year-over-year to $257000.0, compared with a TTM value of $2.2 million through Dec 2025, up 99.1%, and an annual FY2025 reading of $2.2 million, up 99.1% over the prior year.
  • Share-based Compensation hit $257000.0 in Q4 2025 for Rein Therapeutics, down from $1.4 million in the prior quarter.
  • The five-year high for Share-based Compensation was $1.4 million in Q3 2025, with the low at $133000.0 in Q4 2024.
  • Median Share-based Compensation over the past 5 years was $376000.0 (2021), compared with a mean of $443700.0.
  • The sharpest move saw Share-based Compensation tumbled 61.64% in 2024, then soared 184.84% in 2025.
  • Year by year, Share-based Compensation stood at $607000.0 in 2021, then tumbled by 30.15% to $424000.0 in 2022, then plummeted by 36.32% to $270000.0 in 2023, then crashed by 50.74% to $133000.0 in 2024, then soared by 93.23% to $257000.0 in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $257000.0, $1.4 million, and $256000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.